Is Fulcrum Therapeutics, Inc. (FULC) Stock Halal or Haram?
Fulcrum Therapeutics, Inc. (FULC) - Not Halal (Non-Compliant)
Fulcrum Therapeutics, Inc. (FULC) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Biotechnology
Result
Pass
Reason
The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 0.6% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio
Value: 36.9% | Threshold: 30% | Result: Fail
Non-Permissible Income Ratio
Value: 0.0% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 0.00%.No non-permissible income detected in the financial statements. No purification is required based on available data.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
Is Fulcrum Therapeutics, Inc. (FULC) stock halal to invest in?
According to AAOIFI Shariah screening standards, Fulcrum Therapeutics, Inc. (FULC) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
No non-permissible income detected in the financial statements. No purification is required based on available data.
Uses quarterly data
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
United StatesNASDAQHealthcare
Screened using AAOIFI Standard No. 21 on October 20, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Aug 17, 2026. We started recording changes on Oct 19, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Fulcrum Therapeutics, Inc. (FULC) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Fulcrum Therapeutics, Inc.'s interest income ratio is 36.9% of total revenue. AAOIFI standards require this to be below 30%.
FULC is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Fulcrum Therapeutics, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
You can save FULC to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Dividends from Fulcrum Therapeutics, Inc. require purification. Approximately 0.00% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
Does Fulcrum Therapeutics, Inc. have any interest income?
Fulcrum Therapeutics, Inc.'s interest income ratio is 36.9% of total revenue. AAOIFI standards require this to be below 30%.
What guidelines are used to determine if FULC stock is Shariah-compliant?
FULC is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Fulcrum Therapeutics, Inc. stock reviewed for Shariah compliance?
Fulcrum Therapeutics, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Fulcrum Therapeutics, Inc.'s compliance status?
You can save FULC to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Are dividends from Fulcrum Therapeutics, Inc. stock considered halal?
Dividends from Fulcrum Therapeutics, Inc. require purification. Approximately 0.00% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Do I need to pay Zakat on my Fulcrum Therapeutics, Inc. shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
